Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kishore Turaga
Observed names:
Kishore Thuraga,
Turaga, Kishore
Institution:
Biological E (India)
Observed institution:
Biological E (India)
ORCID:
0000-0003-4197-9457
Observed ORCID:
0000-0003-4197-9457
OpenAlex ID:
A5044337627
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials
2022
·
Subhash Thuluva
, Vikram Paradkar
, et al.
·
EBioMedicine
·
76
Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial
2023
·
Subhash Thuluva
, Vikram Paradkar
, et al.
·
Human Vaccines & Immunotherapeutics
·
41
PDF
A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E’s Vi-capsular polysaccharide-CRM 197 conjugate typhoid vaccine (TyphiBEV TM ) in healthy infants, children, and adults in comparison with a licensed comparator
2022
·
Subhash Thuluva
, Vikram Paradkar
, et al.
·
Human Vaccines & Immunotherapeutics
·
34
Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study
2022
·
Subhash Thuluva
, Vikram Paradkar
, et al.
·
Vaccine
·
31
PDF
A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9–12 month old healthy infants
2023
·
Subhash Thuluva
, SubbaReddy Gunneri
, et al.
·
Contemporary Clinical Trials Communications
·
5
Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A prospective double-blind randomized phase III clinical study
2025
·
Subhash Thuluva
, Vikram Paradkar
, et al.
·
IJID Regions
·
2
Selection of Optimum Formulation of RBD-Based Protein Sub-Unit COVID19 Vaccine (Corbevax) Based on Safety and Immunogenicity in an Open-Label, Randomized Phase-1 and 2 Clinical Studies
2022
·
Subhash Thuluva
, Vikram Paradkar
, et al.
·
SSRN Electronic Journal
·
2
A multi-center, randomized, controlled, phase-2/3 study to evaluate the safety and immunogenicity of inactivated Japanese encephalitis vaccine in healthy ≥1 to <3 years old Indian children
2023
·
Subhash Thuluva
, Kishore Turaga
, et al.
·
International Journal of Clinical Trials
PDF
Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial
2023
·
Thuluva, Subhash
, Paradkar, Vikram
, et al.
·
Figshare
Selection of Optimum Formulation of RBD-Based Protein Sub-Unit Covid19 Vaccine (Corbevax) Based on Safety and Immunogenicity in an Open-Label, Randomized Phase-1 and 2 Clinical Studies
2022
·
Subhash Thuluva
, Vikram Paradkar
, et al.
·
SSRN Electronic Journal
Show more works
View as search
Works count:
10
Citation count:
191
H-index:
5
I10-index:
4
Year
Topic
Type
